Journal article
Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG
Abstract
Health-related quality-of-life (HRQoL) data are often included in Phase III clinical trials. We evaluate and classify the value added to Phase III trials by HRQoL outcomes, through a review of the National Cancer Institute of Canada Clinical Trials Group clinical trials experience within various cancer patient populations. HRQoL may add value in a variety of ways, including the provision of data that may contrast with or may support the primary …
Authors
Au H-J; Ringash J; Brundage M; Palmer M; Richardson H; Meyer RM
Journal
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 10, No. 2, pp. 119–128
Publisher
Taylor & Francis
Publication Date
April 2010
DOI
10.1586/erp.10.15
ISSN
1473-7167